Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients

Estimation of bleeding risk is a crucial step in the management of patients with atrial fibrillation (AF). Three bleeding risk–prediction schemes have been derived and validated exclusively in AF populations: HEMORR₂HAGES, HAS-BLED, and ATRIA ((1),2). In the present analysis, the performance of these 3 schemes was tested in the idraparinux arm of the AMADEUS trial (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) (3).

A total of 2,283 patients (67% men; age 70.1 ± 9 years) were randomized to the idraparinux arm. Overall, 74 major bleeding events, 346 any clinically relevant bleeding events, and 62 deaths occurred over 311 ± 161 days of follow-up. Specific data for each risk score are shown in (Table 1). Read More